Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease

Cohen‐Mekelburg, Shirley; Wallace, Beth; Van, Tony; Wiitala, Wyndy L.; Govani, Shail M.; Burns, Joseph E.; Lipson, Rachel; Yun, Huifeng; Hou, Jason K.; Dominitz, Jason A.; Waljee, Akbar K.

doi:10.1001/jamanetworkopen.2021.0313

Cited by 10 publications

(9 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, it is known that TNF-α, IL-1β, and IL-6 are known to be closely related to the progression of enteritis. TNF-α is a key factor in the pathogenesis of IBD [1,55]. The expression of TNF-α in the inflammatory site of CD patients is significantly increased, which activates monocytes, macrophages, lymphocytes, and neutrophils in the inflammatory microenvironment, which plays a key role in the amplification and prolongation of inflammation [56].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic efficacy of human adipose mesenchymal stem cells in Crohn’s colon fibrosis is improved by IFN-γ and kynurenic acid priming through indoleamine 2,3-dioxygenase-1 signaling

Zhang

et al. 2022

Stem Cell Res Ther

View full text Add to dashboard Cite

Background Inflammatory bowel diseases (IBD) are chronic relapsing–remitting inflammatory diseases of the gastrointestinal tract that are typically categorized into two subtypes: Crohn's disease (CD) and ulcerative colitis (UC). Although MSCs therapy has achieved encouraging outcomes in IBD therapy, objective responses are limited in colon fibrosis stenosis owing to the complicated microenvironment of CD and MSCs heterogeneity of quality. Here, we chose IFN-γ and kynurenic acid (KYNA) to overcome the low response and heterogeneity of human adipose-derived MSCs (hADSCs) to treat IBD and expand the therapeutic effects based on the excellent ability of IFN-γ and KYNA to promote indoleamine 2,3-dioxygenase-1 (IDO-1) signaling, providing a potential protocol to treat IBD and fibrosis disease. Methods hADSCs were isolated, cultured, and identified from human abdominal adipose tissue. The CD pathology-like acute colitis and chronic colon fibrosis rat model was induced by 2,4,6-trinitrobenzen sulfonic acid (TNBS). hADSCs were pretreated in vitro with IFN-γ and KYNA and then were transplanted intravenously at day 1 and 3 of TNBS administration in colitis along with at day 1, 15, and 29 of TNBS administration in chronic colonic fibrosis. Therapeutic efficacy was evaluated by body weights, disease activity index, pathological staining, real-time PCR, Western blot, and flow cytometry. For knockout of IDO-1, hADSCs were transfected with IDO-1-targeting small gRNA carried on a CRISPR-Cas9-lentivirus vector. Results hADSCs treated with IFN-γ and KYNA significantly upregulated the expression and secretion of IDO-1, which has effectively ameliorated CD pathology-like colitis injury and fibrosis. Notably, the ability of hADSCs with IDO-1 knockout to treat colitis was significantly impaired and diminished the protective effects of the primed hADSCs with IFN-γ and KYNA. Conclusion Inflammatory cytokines IFN-γ- and KYNA-treated hADSCs more effectively alleviate TNBS-induced colitis and colonic fibrosis through an IDO-1-dependent manner. Primed hADSCs are a promising new strategy to improve the therapeutic efficacy of MSCs and worth further research.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic efficacy of human adipose mesenchymal stem cells in Crohn’s colon fibrosis is improved by IFN-γ and kynurenic acid priming through indoleamine 2,3-dioxygenase-1 signaling

Zhang

et al. 2022

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…50 Studies in IBD have suggested that steroids, but not infliximab, are the main driver of adverse events in patients on these agents, including mortality, specifically with death related to major cardiac events or hip fractures. 51,52 Adverse effects of steroids have been observed in patients receiving ICIs as well. In a retrospective analysis of patients with lung cancer treated with ICIs who required at least 3 weeks of prednisone at a dose of 20 mg or higher, 90% of the patients had adverse events attributable to steroids, including altered mood or sleep patterns (52%), increased BMI (45%), and infection (32%).…”

Section: Safety Considerationsmentioning

confidence: 99%

Accelerating the Evolution of Immune-Related Enterocolitis Management

Faleck

Dougan

Tello

et al. 2023

JCO

View full text Add to dashboard Cite

“…(1) clinical studies, such as cohort or case-control studies; (2) studies that evaluated the occurrence of psoriasis after anti-TNF therapy in patients with IBD; (3) studies in which the number of patients required for our meta-analysis was described; and (4) studies written in English. The exclusion criteria were as follows: (1) nonhuman studies; (2) reviews, editorials, expert opinions, letters, or case reports; (3) studies in which did not deal with anti-TNF-treated patients with IBD; (4) studies in which the order of psoriasis occurrence and the initiation of anti-TNF treatment was unclear; and (5) studies with severe heterogeneity.…”

Section: Study Selectionmentioning

confidence: 99%

“…Antitumor necrosis factor (TNF) agents, including infliximab, adalimumab, golimumab, and certolizumab, are effective for induction and maintenance of remission in patients with IBD and reduce the risk of surgery and mortality. [ 1 , 2 ] However, long-term usage of anti-TNF agents is associated with complications, such as infection, postoperative wound healing failure, malignancy, and immune-mediated diseases. [ 3 , 4 ] Psoriasis, one of the immune-mediated diseases, can occur in IBD patients with anti-TNF agents, but ironically anti-TNF agents are also effective to control psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis

Park

Koh

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Recent case reports have suggested that anti-tumor necrosis factor (TNF) agents are associated with an increased risk of developing psoriasis in patients with inflammatory bowel disease (IBD). Aims: This meta-analysis of published studies aimed to evaluate the association between anti-TNF treatment and psoriasis in patients with IBD. Methods: An electronic search for original articles published before April 7, 2022, was performed using PubMed, EMBASE, and the Cochrane Library. Independent reviewers conducted the article screening and data extraction. Psoriasis development between anti-TNF-treated and anti-TNF-naïve patients was compared. Patients with ulcerative colitis and Crohn disease were compared with determine the differences in anti-TNF-induced psoriasis. Also, psoriasis development was compared according to the types of anti-TNF agents. Random-effects model meta-analyses, network meta-analysis, funnel plot asymmetry, Begg rank correlation test, and Egger regression test were performed to generate summary estimates and explore the possibility of publication bias. Results: We analyzed a total of 10,778 articles searched and 14 articles were selected to analyze. There was no significant difference in psoriasis development between anti-TNF-treated and anti-TNF-naïve patients (relative risk = 1.14; 95% confidence interval = 0.77-1.68). No differences were found for psoriasis development between anti-TNF-treated ulcerative colitis and Crohn disease patients (relative risk = 1.30; 95% confidence interval = 0.87-1.95). No significant difference was reported with respect to psoriasis development according to the types of anti-TNF agents. We found no definitive publication bias in our analyses. Conclusions: Anti-TNF treatment did not contribute to the psoriasis development in patients with IBD. Based on our study, anti-TNF agents may be used for IBD treatment without concern for psoriasis development.

show abstract

Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease

Cited by 10 publications

References 29 publications

Therapeutic efficacy of human adipose mesenchymal stem cells in Crohn’s colon fibrosis is improved by IFN-γ and kynurenic acid priming through indoleamine 2,3-dioxygenase-1 signaling

Therapeutic efficacy of human adipose mesenchymal stem cells in Crohn’s colon fibrosis is improved by IFN-γ and kynurenic acid priming through indoleamine 2,3-dioxygenase-1 signaling

Accelerating the Evolution of Immune-Related Enterocolitis Management

Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis

Contact Info

Product

Resources

About